FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3036129156> ?p ?o ?g. }

• W3036129156 abstract "Abstract Background The Philadelphia chromosome (Ph), which leads to the creation and expression of the fusion gene product BCR-ABL, underlines the pathogenesis of chronic myelogenous leukemia (CML) and a fraction of adult and pediatric acute B-lymphoblastic leukemia (B-ALL). The BCR-ABL tyrosine kinase inhibitors (TKIs) have shown a remarkable clinical activity in patients with CML, but their efficacy in treating Ph + B-ALL is limited. Identifying additional therapeutic targets is important for the effective treatment of Ph + B-ALL. Methods Activation of the JNK signaling pathway in human and mouse BCR-ABL + B-ALL cells with or without dasatinib treatment was analyzed by Western blotting. JNK was inhibited either by RNA interference or chemical inhibitors, such as JNK-IN-8. The effect of JNK inhibition with or without BCR-ABL TKI dasatinib on BCR-ABL + B-ALL cells was analyzed by the CellTiter-Glo® Luminescent Cell Viability Assay. The in vivo effects of JNK-IN-8 and dasatinib alone or in combination were tested using a BCR-ABL induced B-ALL mouse model. Results We found that the c-JUN N-terminal kinase (JNK) signaling pathway is abnormally activated in both human and mouse BCR-ABL + B-ALL cells, but the BCR-ABL TKI does not inhibit JNK activation in these cells. Inhibition of JNK, either by RNAi-mediated downregulation or by JNK inhibitors, could significantly reduce viability of Ph + B-ALL cells. JNK inhibition by RNAi-mediated downregulation or JNK inhibitors also showed a synergistic effect with the BCR-ABL TKI, dasatinib, in killing Ph + B-ALL cells in vitro. Furthermore, a potent JNK inhibitor, JNK-IN-8, in combination with dasatinib markedly improved the survival of mice with BCR-ABL induced B-ALL, as compared to the treatment with dasatinib alone. Conclusions Our findings indicate that simultaneously targeting both BCR-ABL and JNK kinase might serve as a promising therapeutic strategy for Ph + B-ALL." @default.
• W3036129156 created "2020-06-25" @default.
• W3036129156 creator A5014538185 @default.
• W3036129156 creator A5016841529 @default.
• W3036129156 creator A5022121191 @default.
• W3036129156 creator A5039106537 @default.
• W3036129156 creator A5040229329 @default.
• W3036129156 creator A5045768839 @default.
• W3036129156 creator A5051062987 @default.
• W3036129156 creator A5058473468 @default.
• W3036129156 creator A5077153113 @default.
• W3036129156 creator A5083766150 @default.
• W3036129156 date "2020-06-18" @default.
• W3036129156 modified "2023-10-18" @default.
• W3036129156 title "Combination therapy of BCR-ABL-positive B cell acute lymphoblastic leukemia by tyrosine kinase inhibitor dasatinib and c-JUN N-terminal kinase inhibition" @default.
• W3036129156 cites W1987821813 @default.
• W3036129156 cites W1989427470 @default.
• W3036129156 cites W1994309500 @default.
• W3036129156 cites W1998809668 @default.
• W3036129156 cites W2011760895 @default.
• W3036129156 cites W2016656445 @default.
• W3036129156 cites W2022758856 @default.
• W3036129156 cites W2028829513 @default.
• W3036129156 cites W2037154482 @default.
• W3036129156 cites W2039201527 @default.
• W3036129156 cites W2041535798 @default.
• W3036129156 cites W2062289724 @default.
• W3036129156 cites W2064096260 @default.
• W3036129156 cites W2065851457 @default.
• W3036129156 cites W2066211653 @default.
• W3036129156 cites W2069023125 @default.
• W3036129156 cites W2076785980 @default.
• W3036129156 cites W2077945404 @default.
• W3036129156 cites W2084472730 @default.
• W3036129156 cites W2096045098 @default.
• W3036129156 cites W2107268345 @default.
• W3036129156 cites W2107495112 @default.
• W3036129156 cites W2110471949 @default.
• W3036129156 cites W2120366344 @default.
• W3036129156 cites W2145678539 @default.
• W3036129156 cites W2152024997 @default.
• W3036129156 cites W2169758210 @default.
• W3036129156 cites W2170444099 @default.
• W3036129156 cites W2273132970 @default.
• W3036129156 cites W2344488712 @default.
• W3036129156 cites W2496712281 @default.
• W3036129156 cites W2533551977 @default.
• W3036129156 cites W2559189946 @default.
• W3036129156 cites W2564978332 @default.
• W3036129156 cites W2755573776 @default.
• W3036129156 cites W2884510934 @default.
• W3036129156 cites W2902532424 @default.
• W3036129156 cites W2918708984 @default.
• W3036129156 cites W2935966636 @default.
• W3036129156 doi "https://doi.org/10.1186/s13045-020-00912-3" @default.
• W3036129156 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/7302132" @default.
• W3036129156 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/32552902" @default.
• W3036129156 hasPublicationYear "2020" @default.
• W3036129156 type Work @default.
• W3036129156 sameAs 3036129156 @default.
• W3036129156 citedByCount "11" @default.
• W3036129156 countsByYear W30361291562020 @default.
• W3036129156 countsByYear W30361291562021 @default.
• W3036129156 countsByYear W30361291562022 @default.
• W3036129156 countsByYear W30361291562023 @default.
• W3036129156 crossrefType "journal-article" @default.
• W3036129156 hasAuthorship W3036129156A5014538185 @default.
• W3036129156 hasAuthorship W3036129156A5016841529 @default.
• W3036129156 hasAuthorship W3036129156A5022121191 @default.
• W3036129156 hasAuthorship W3036129156A5039106537 @default.
• W3036129156 hasAuthorship W3036129156A5040229329 @default.
• W3036129156 hasAuthorship W3036129156A5045768839 @default.
• W3036129156 hasAuthorship W3036129156A5051062987 @default.
• W3036129156 hasAuthorship W3036129156A5058473468 @default.
• W3036129156 hasAuthorship W3036129156A5077153113 @default.
• W3036129156 hasAuthorship W3036129156A5083766150 @default.
• W3036129156 hasBestOaLocation W30361291561 @default.
• W3036129156 hasConcept C104317684 @default.
• W3036129156 hasConcept C121608353 @default.
• W3036129156 hasConcept C125418893 @default.
• W3036129156 hasConcept C126322002 @default.
• W3036129156 hasConcept C138626823 @default.
• W3036129156 hasConcept C170493617 @default.
• W3036129156 hasConcept C184235292 @default.
• W3036129156 hasConcept C185592680 @default.
• W3036129156 hasConcept C203014093 @default.
• W3036129156 hasConcept C2776960273 @default.
• W3036129156 hasConcept C2778461978 @default.
• W3036129156 hasConcept C2778820342 @default.
• W3036129156 hasConcept C2778904597 @default.
• W3036129156 hasConcept C2779087070 @default.
• W3036129156 hasConcept C2779536868 @default.
• W3036129156 hasConcept C42362537 @default.
• W3036129156 hasConcept C43907098 @default.
• W3036129156 hasConcept C502942594 @default.
• W3036129156 hasConcept C55493867 @default.
• W3036129156 hasConcept C62478195 @default.
• W3036129156 hasConcept C71924100 @default.
• W3036129156 hasConcept C86339819 @default.
• W3036129156 hasConcept C86803240 @default.

• next